default author photo

Abdul Rafeh Naqash

University of Oklahoma - Stephenson Cancer Center

SCHOLARLY PAPERS

2

DOWNLOADS

154

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older with Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in Pd-L1 High (≥50%) Patients

Number of pages: 35 Posted: 03 Jan 2025
Harvard University - Dana-Farber Cancer Institute, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Imperial College London, affiliation not provided to SSRN, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, University of California, Los Angeles (UCLA), Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, affiliation not provided to SSRN, MD Anderson Cancer Center - Department of Gastroenterology, Hepatology and Nutrition, affiliation not provided to SSRN, University of Kansas - Cancer Center, University of Kansas - University of Kansas Medical Center, Vanderbilt University, Vanderbilt University - Medical Center, Imperial College London, Harvard University - Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute and University of Oklahoma - Stephenson Cancer Center
Downloads 83 (783,685)

Abstract:

Loading...

Non-Small Cell Lung Cancer, immunotherapy, pembrolizumab, Tumor microenvironment, Tumor immunophenotype, Older adults

2.

Reproducible Safety and Efficacy of Atezolizumab Plus Bevacizumab for HCC in Clinical Practice: Results of the AB-Real Study

Number of pages: 19 Posted: 09 Jul 2022
Imperial College London - Hammersmith Hospital, CHA University - CHA Bundang Medical Center, Imperial College London - Hammersmith Hospital, Kindai University, Mount Sinai Health System - Division of Hematology/ Oncology, Mount Sinai Health System - Precision Immunology Institute, Mount Sinai Health System - Division of Hematology/ Oncology, University of Kansas - Cancer Center, University of Kansas - Cancer Center, IRCCS Humanitas Research Hospital, IRCCS Humanitas Research Hospital, IRCCS Humanitas Research Hospital, University of Vienna, University of Vienna, Medical University of Vienna - Vienna Hepatic Hemodynamic Laboratory, Royal Marsden NHS Foundation Trust, National Yang Ming University - Taipei Veterans General Hospital, University of Texas at Dallas - Southwestern Medical Center, University of Oklahoma - Stephenson Cancer Center, University of Pisa, University of Pisa, University of Pisa, University of Freiburg - Faculty of Medicine, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, University of Hamburg - University Medical Center Hamburg-Eppendorf, University of Hamburg - University Medical Center Hamburg-Eppendorf, University of Hamburg - University Medical Center Hamburg-Eppendorf, University of Hamburg - University Medical Center Hamburg-Eppendorf, University Medical Center Mainz, Kindai University - Department of Gastroenterology and Hepatology, IRCCS Humanitas Research Hospital, University of Texas at Dallas - Division of Digestive and Liver Diseases, Imperial College London, Imperial College London - Hammersmith Hospital, Roche, CHA University - CHA Bundang Medical Center and Imperial College London
Downloads 71 (867,774)

Abstract:

Loading...

Advanced HCC, systemic treatment, first line, atezolizumab, bevacizumab